Suppr超能文献

药代动力学和药物致畸作用中的物种差异。

Species differences in pharmacokinetics and drug teratogenesis.

作者信息

Nau H

出版信息

Environ Health Perspect. 1986 Dec;70:113-29. doi: 10.1289/ehp.8670113.

Abstract

Interspecies differences in regard to the teratogenicity of drugs can be the result of differing pharmacokinetic processes that determine the crucial concentration-time relationships in the embryo. Maternal absorption, as well as distribution, of the drugs does not usually show great species differences. The first-pass effect after oral application is often more pronounced in animals than man (e.g., valproic acid, 13-cis-retinoic acid), although in some cases the reverse was found (e.g., hydrolysis of valpromide). Existing differences can be adjusted by appropriate choice of the administration route and measurements of drug levels. Many variables determine the placental transfer of drugs: developmental stage, type of placenta, properties of the drug. Even closely related drugs (e.g., retinoids) may differ greatly in regard to placental transfer. Maternal protein binding is an important determinant of placental transfer, since only the free concentration in maternal plasma can equilibrate with the embryo during organogenesis; this parameter differs greatly across species (e.g., valproic acid: five times higher free fractions in mouse and hamster than in monkey and man). The metabolic pattern has not yet been demonstrated to be a major cause of species differences, although recent evidence on phenytoin and thalidomide support the hypothesis that some species differences can be the result of differing activation/deactivation pathways. Laboratory animals usually have a much higher rate of drug elimination than man. Drastic drug level fluctuations are therefore present during teratogenicity testing in animals, but not to the same degree in human therapy. It must, therefore, be investigated if peak concentrations (such as for valproic acid and possibly caffeine) or the area under the concentration-time curve (AUC) (such as for cyclophosphamide and possibly retinoids) correlate with the teratogenic response. Only then is a rational and scientific basis for interspecies comparison possible. It is concluded that the prediction of the human response based on animal studies can be improved by consideration of the appropriate pharmacokinetic determinants.

摘要

药物致畸性的种间差异可能是由不同的药代动力学过程导致的,这些过程决定了胚胎中关键的浓度 - 时间关系。药物在母体中的吸收以及分布通常不会表现出很大的种间差异。口服给药后的首过效应在动物中往往比在人类中更明显(例如丙戊酸、13 - 顺式维甲酸),尽管在某些情况下发现了相反的情况(例如丙戊酰胺的水解)。现有的差异可以通过适当选择给药途径和测量药物水平来调整。许多变量决定了药物的胎盘转运:发育阶段、胎盘类型、药物特性。即使是密切相关的药物(例如类视黄醇)在胎盘转运方面也可能有很大差异。母体蛋白结合是胎盘转运的一个重要决定因素,因为在器官形成过程中,只有母体血浆中的游离浓度才能与胚胎达到平衡;这个参数在不同物种之间差异很大(例如丙戊酸:小鼠和仓鼠中的游离分数比猴子和人类高五倍)。尽管最近关于苯妥英和沙利度胺的证据支持了某些种间差异可能是由不同的激活/失活途径导致的这一假设,但代谢模式尚未被证明是种间差异的主要原因。实验动物的药物消除率通常比人类高得多。因此,在动物致畸性试验期间会出现剧烈的药物水平波动,但在人类治疗中程度不同。因此,必须研究峰值浓度(如丙戊酸和可能的咖啡因)或浓度 - 时间曲线下面积(AUC)(如环磷酰胺和可能的类视黄醇)是否与致畸反应相关。只有这样,种间比较才有合理和科学的基础。得出的结论是,通过考虑适当的药代动力学决定因素,可以改进基于动物研究对人类反应的预测。

相似文献

引用本文的文献

2
and Pharmacokinetic Studies of a Dual Topoisomerase I/II Inhibitor.一种双拓扑异构酶I/II抑制剂的药代动力学研究
ACS Pharmacol Transl Sci. 2025 Mar 12;8(4):1050-1071. doi: 10.1021/acsptsci.4c00596. eCollection 2025 Apr 11.
3
Thalidomide-induced limb malformations: an update and reevaluation.沙利度胺所致肢体畸形:最新进展与重新评估
Arch Toxicol. 2025 May;99(5):1643-1747. doi: 10.1007/s00204-024-03930-z. Epub 2025 Apr 8.
8
Challenges in Translating Regenerative Therapies for Spinal Cord Injury.脊髓损伤再生治疗的翻译挑战。
Top Spinal Cord Inj Rehabil. 2023 Fall;29(Suppl):23-43. doi: 10.46292/sci23-00044S. Epub 2023 Nov 17.

本文引用的文献

1
BIOCHEMICAL EFFECTS OF DRUGS ON THE MAMMALIAN CONCEPTUS.药物对哺乳动物孕体的生化作用。
Ann N Y Acad Sci. 1965 Mar 12;123:252-62. doi: 10.1111/j.1749-6632.1965.tb12264.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验